{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:06:25Z","timestamp":1776405985927,"version":"3.51.2"},"reference-count":58,"publisher":"Cambridge University Press (CUP)","issue":"S1","license":[{"start":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T00:00:00Z","timestamp":1562716800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>Opioid use disorder (OUD) is a disorder that can lead to several negative outcomes, including overdose and death. A variety of opioids can be abused by individuals including both prescribed and non-prescribed opioids. Continued opioid use can be driven by negative affective states associated with opioid withdrawal. Several treatments exist in the field including medication assisted treatments such as methadone, buprenorphine, and naltrexone. Treatments such as clonidine and lofexidine can also be used to assist with decreasing withdrawal symptoms. Increasing adherence to treatment can further improve patient outcomes and promote continuation with treatment. A variety of methods to reduce relapse can also be utilized such as opioid agonists and maintenance therapy. According to the Centers for Disease Control, opioid overdoses contributed to 67.8% of overdose deaths in 2017.<\/jats:p>","DOI":"10.1017\/s109285291900110x","type":"journal-article","created":{"date-parts":[[2019,7,10]],"date-time":"2019-07-10T10:47:35Z","timestamp":1562755655000},"page":"14-24","source":"Crossref","is-referenced-by-count":6,"title":["Keeping Up with Clinical Advances: Opioid Use Disorder"],"prefix":"10.1017","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5323-3663","authenticated-orcid":false,"given":"Biren","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Kosten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2019,7,10]]},"reference":[{"key":"S109285291900110X_ref13","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903037168"},{"key":"S109285291900110X_ref58","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.11.033"},{"key":"S109285291900110X_ref49","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1965.03090080008002"},{"key":"S109285291900110X_ref47","first-page":"578","article-title":"The Effectiveness of Methadone Maintenance Treatment","volume":"326","author":"Ball","year":"1992","journal-title":"N Engl J Med."},{"key":"S109285291900110X_ref45","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000087"},{"key":"S109285291900110X_ref44","volume-title":"Neuroscience of Opiates for Addiction Medicine","volume":"223","author":"Zhou","year":"2015"},{"key":"S109285291900110X_ref43","unstructured":"43. New York State Department of Health. How to Use Injection Naloxone for Opioid Overdose.; 2015."},{"key":"S109285291900110X_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-018-0402-3"},{"key":"S109285291900110X_ref33","volume-title":"Suboxone Medication Guide","year":"2018"},{"key":"S109285291900110X_ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2012.07.002"},{"key":"S109285291900110X_ref31","unstructured":"31. Substance Abuse and Mental Health Services Administration. Buprenorphine Training for Physicians. SAMSHA. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/training-resources\/buprenorphine-physician-training. Published 2018. Accessed January 2, 2019."},{"key":"S109285291900110X_ref57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1550"},{"key":"S109285291900110X_ref12","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200603000-00025"},{"key":"S109285291900110X_ref19","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.09m05080ecr"},{"key":"S109285291900110X_ref16","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2014.14081014"},{"key":"S109285291900110X_ref11","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2009.110"},{"key":"S109285291900110X_ref50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022164"},{"key":"S109285291900110X_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.05.030"},{"key":"S109285291900110X_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.02.033"},{"key":"S109285291900110X_ref55","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13818"},{"key":"S109285291900110X_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jemermed.2016.08.026"},{"key":"S109285291900110X_ref25","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1977.01770150119014"},{"key":"S109285291900110X_ref2","first-page":"705","volume":"59","year":"2010","journal-title":"Morb Mortal Wkly Rep."},{"key":"S109285291900110X_ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1995.03530160059035"},{"key":"S109285291900110X_ref26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002207.pub4"},{"key":"S109285291900110X_ref56","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107"},{"key":"S109285291900110X_ref15","first-page":"39","article-title":"Outpatient Opiate Detoxification with Clonidine","volume":"43","author":"Washton","year":"1982","journal-title":"J Clin Psychiatry."},{"key":"S109285291900110X_ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0640-8"},{"key":"S109285291900110X_ref54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480200058024"},{"key":"S109285291900110X_ref28","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain Physician."},{"key":"S109285291900110X_ref1","volume-title":"NSDUH.","author":"McCance-Katz","year":"2017"},{"key":"S109285291900110X_ref42","unstructured":"42. Adapt Pharma Inc. NARCAN (Naloxone Hydrochloride) Nasal Spray.; 2015."},{"key":"S109285291900110X_ref51","doi-asserted-by":"crossref","first-page":"E119","DOI":"10.36076\/ppj.2014\/17\/E119","article-title":"Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011","volume":"17","author":"Atluri","year":"2014","journal-title":"Pain Physician."},{"key":"S109285291900110X_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60358-9"},{"key":"S109285291900110X_ref24","unstructured":"24. Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2017 Data on Substance Abuse Treatment Facilities. Vol BHSIS Seri.; 2017."},{"key":"S109285291900110X_ref35","doi-asserted-by":"publisher","DOI":"10.2174\/1570159043359477"},{"key":"S109285291900110X_ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2013.08.008"},{"key":"S109285291900110X_ref41","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6501e1"},{"key":"S109285291900110X_ref21","doi-asserted-by":"publisher","DOI":"10.1111\/add.12208"},{"key":"S109285291900110X_ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2014.04.012"},{"key":"S109285291900110X_ref36","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1735"},{"key":"S109285291900110X_ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2011.01.008"},{"key":"S109285291900110X_ref38","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2006.09.012"},{"key":"S109285291900110X_ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra020617"},{"key":"S109285291900110X_ref18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-5-18"},{"key":"S109285291900110X_ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2018.3126"},{"key":"S109285291900110X_ref53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2013.10.018","article-title":"Predictors of non-prescribed opioid use after one year of methadone treatment: an attributable-risk approach (ANRS-Methaville trial)","volume":"135","author":"Caroline","year":"2014","journal-title":"Drug Alcohol Depend."},{"key":"S109285291900110X_ref6","first-page":"2013","article-title":"Drug and Opioid-Involved Overdose Deaths-United States","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR."},{"key":"S109285291900110X_ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1973.03220060039009"},{"key":"S109285291900110X_ref7","unstructured":"7. U.S. Opioid Prescribing Rate Maps. Centers for Disease Control. https:\/\/www.cdc.gov\/drugoverdose\/maps\/rxrate-maps.html. Published 2018. Accessed December 30, 2018."},{"key":"S109285291900110X_ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2010.00871.x"},{"key":"S109285291900110X_ref4","doi-asserted-by":"publisher","DOI":"10.1080\/10826080701409404"},{"key":"S109285291900110X_ref52","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.2174\/13816128113199990623","article-title":"Predictors of Non-Adherence to Methadone Maintenance Treatment in Opioid-Dependent Individuals: Implications for Clinicians","volume":"20","author":"Spire","year":"2014","journal-title":"Curr Pharm Des."},{"key":"S109285291900110X_ref32","unstructured":"32. Substance Abuse and Mental Health Services Administration. Apply to Increase Patient Limits. SAMSHA. https:\/\/www.samhsa.gov\/medication-assisted-treatment\/buprenorphine-waiver-management\/increase-patient-limits. Published 2017. Accessed January 2, 2019."},{"key":"S109285291900110X_ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.366"},{"key":"S109285291900110X_ref14","doi-asserted-by":"publisher","DOI":"10.1002\/ejp.1305"},{"key":"S109285291900110X_ref30","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/PRA.0000000000000154","article-title":"Buprenorphine Prescribing: To Expand or Not to Expand","volume":"22","author":"Xi","year":"2016","journal-title":"J Psychiatr Pract."},{"key":"S109285291900110X_ref22","volume-title":"Naltrexone Extended Release Injectable Suspension: Medication Guide","year":"2010"}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S109285291900110X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,23]],"date-time":"2022-09-23T14:16:25Z","timestamp":1663942585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S109285291900110X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,10]]},"references-count":58,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S109285291900110X"],"URL":"https:\/\/doi.org\/10.1017\/s109285291900110x","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,10]]}}}